Al-Taie, AnmarBulbul, Ece Ozcan2024-05-192024-05-1920241061-186X1029-2330https://doi.org10.1080/1061186X.2023.2295803https://hdl.handle.net/20.500.12713/4818Monoclonal antibodies (mAbs) are integral to cancer treatment over conventional non-specific therapy methods. This study provides a scoping review of the clinically approved mAbs, focusing on the current application of different nanocarrier technologies as drug delivery targets for mAb-conjugated nanoparticles (NPs) as potential features for breast cancer (BC) treatment. An extensive literature search was conducted between the years 2000 and 2023 using various sources of databases. The first part covered mAb classification, types, and mechanisms of action, pharmacokinetics and clinical applications in BC. The second part covered polymeric, lipid and inorganic-based NPs, which are a variety of mAb-conjugated NPs targeting BC. A total of 20 relevant studies were enrolled indicating there are three different types of nanoparticular systems (polymeric NPs, inorganic NPs and lipid-based NPs) that can be used for BC treatment by being loaded with various active substances and conjugated with these antibodies. While mAbs have altered the way in cancer treatment due to targeting cancer cells specifically, the delivery of mAbs with nanoparticulate systems is important in the treatment of BC, as NPs are still being investigated as distinctive and promising drug delivery methods that can be employed for effective treatment of BC.eninfo:eu-repo/semantics/closedAccessBreast CancerImmunotherapyNanoparticlesMonoclonal AntibodiesTargeting Drug DeliveryReview Article321455638096045WOS:0011344791000012-s2.0-85181211140N/A10.1080/1061186X.2023.2295803Q1